In:
Pulmonary Therapy, Springer Science and Business Media LLC, Vol. 6, No. 2 ( 2020-12), p. 151-158
Abstract:
In pediatric patients with asthma, measurements of forced expiratory volume in 1 s (FEV 1 ) may be normal or may not correlate with symptom severity. Forced expiratory flow at 25–75% of the vital capacity (FEF 25–75% ) is a potentially more sensitive parameter for assessing peripheral airway function. This post hoc analysis compared FEF 25–75% with FEV 1 as an endpoint to assess bronchodilator responsiveness in children with asthma. Methods Change from baseline in trough FEF 25–75% and trough FEV 1 following treatment with either tiotropium (5 µg or 2.5 µg) or placebo Respimat ® was analyzed in four phase III trials in children (aged 6–11 years) and adolescents (aged 12–17 years) with symptomatic moderate (VivaTinA-asthma ® and PensieTinA-asthma ® ) and mild (CanoTinA-asthma ® and RubaTinA-asthma ® ) asthma. Data from all treatment arms were pooled and correlations between FEF 25–75% and FEV 1 were calculated and analyzed. Results A total of 1590 patients were included in the analysis. Tiotropium Respimat ® consistently improved FEF 25–75% and FEV 1 versus placebo, although in adolescents with severe asthma, the observed improvements were not statistically significant. Improvements in FEF 25–75% response with tiotropium versus placebo were largely more pronounced than improvements in FEV 1 . Statistical assessment of the correlation of FEV 1 and FEF 25–75% showed moderate-to-high correlations (Pearson’s correlation coefficients 0.73–0.80). Conclusions In pediatric patients, FEF 25–75% may be a more sensitive measure to detect treatment response, certainly to tiotropium, than FEV 1 and should be evaluated as an additional lung function measurement.
Type of Medium:
Online Resource
ISSN:
2364-1754
,
2364-1746
DOI:
10.1007/s41030-020-00117-6
Language:
English
Publisher:
Springer Science and Business Media LLC
Publication Date:
2020
detail.hit.zdb_id:
2842522-4
Permalink